TEVA stock news · Teva Pharmaceutical Industries Ltd
Get alerts for TEVA
Follow Teva Pharmaceutical Industries Ltd (TEVA) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for TEVATeva Pharmaceutical Industries Ltd is changing its leadership by adding new directors and officers.
NeutralTeva elected health-care executive David Brailer to its board. His experience may add perspective, but the filing reports no change to Teva’s business outlook.
The FDA has given the green light for Teva's new monthly shot for treating schizophrenia.
Good for TEVATeva won U.S. approval for Weltruza, a monthly schizophrenia injection. Trial results and the planned launch support Teva, though sales have not started.
Nine additional pharmaceutical partnerships announced by Trump increase total agreements to 26 — RFK Jr. shares insights on 'deeply emotional' discussions with the President.
Bad for TEVATeva is part of the new agreements and also agreed to donate APIs, actions that together imply pricing/operational impacts and short-term cost or revenue pressure.
Aurinia Pharmaceuticals and Teva resolve patent conflict regarding kidney disease medication.
Bad for TEVATeva's ability to launch its generic product is delayed, which could negatively affect its market share in the kidney disease drug segment.